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ABSTRACT
Oral contraceptive (OC) pills contain estrogen and progestin that are synthetic analogs of natural hormones. These synthetic hormones affect 
the hypothalamus-pituitary-gonadal axis of the female reproductive system. There are many types of contraceptives; most of the OC pills prevent 
pregnancy by inhibiting ovulation. Estrogen and progestin are two female reproductive hormones that are critical. Typically, estradiol is produced 
by growing follicle (ovaries) which stimulates the hypothalamus to produce the gonadotropin-releasing hormone, which further stimulates the 
anterior pituitary to produce follicle-stimulating hormone (FSH) and luteinizing hormone (LH). LH production triggers the ovulation. Similarly, the 
progesterone is produced by corpus luteum (ovaries), which triggers the production of FSH and LH. There are many types of progesterone available. 
Long-term usage of synthetic estrogen and progesterone can disturb the balance between the level of these hormones in the body. This imbalance may 
lead to severe side effects such as breast cancer, cervical cancer, thrombosis, direct impact on the brain, and infertility.
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INTRODUCTION
Contraception is a method to prevent unwanted pregnancy. Combined 
oral contraceptives (COCs) have become a popular method of birth 
control due to their contraceptive efficacy and good tolerability 
profile [1]. These pills contain hormones that act on the reproductive 
system of female leading to contraceptives such as estrogen and 
progesterone. OCs are the combination of estrogen and progestin or 
only progestin. Over the years, OCs have developed through gradually 
reducing the dose of ethinylestradiol (EE) and introducing 17-β 
estradiol, and various generations of progestin [2]. There are manytypes 
of estrogen and progesterone being used in pills like mestranol is a class 
of estrogen, and the 3-methyl ether of EE and norethynodrel is a type 
of progestin; its dose was 9.85 mg per pill initially. In clinical studies, 
the efficiency of contraceptive was excellent, but this drug caused 
many side effects such as nausea, dizziness, headaches, stomachaches, 
and vomiting; these are the symptoms that had presented by the 17% 
women undergoing the clinical studies. Though, the death of a female 
had been reported who was taking the contraceptive pills in 1961. 
Although after so many years, OCs have developed by reducing the 
dose of estrogen and by discovering a new generation of progestins, 
and other routes of COC administration have been developed [3]. The 
findings of the previous research show some severe side effects of these 
pills. Thus, this short study is focused on the overview of the female 
reproductive system and its regulation, hormonal contraceptive pills, 
mechanism of action of these drugs, and side effects of OC pills.
OVERVIEW OF FEMALE REPRODUCTIVE CYCLE
The balance between estrogen and progesterone handles the 
development and maintenance of the female reproductive system. Cellular 
differentiation is regulated by progesterone while estrogen controls cell 
proliferation. Thus, uterine endometrium has 3 phases (Fig.1)
1. The follicular phase (estrogen dominant) is a growth phase where 
uterine glands grow and proliferate
2. During secretory (luteal) phase, (progesterone dominant) glands get 
tightly coiled, and secrete
3. During menses, spiral arteries constrict, and endometrium sloughs.
REGULATION OF REPRODUCTIVE HORMONES IN FEMALE
The hypothalamus is responsible for the secretion of gonadotropin-
releasing hormones (GnRH), which then stimulates the anterior 
pituitary to release follicle-stimulating hormones (FSH) and luteinizing 
hormones (LHs). FSH stimulates follicle growth, maturation of ovum 
leading to the release of estradiol from follicles. High levels of estradiol 
for a sufficient period stimulate sudden secretion of LHRH (GnRH-
positive feedback), which induces a surge of LH (and FSH) secretes 
from the anterior pituitary (Fig. 2). LH surge leads to ovulation and 
assists the development of corpus luteum. Corpus luteum then releases 
progesterone. Increased levels of estrogen and progesterone will 
signal anterior pituitary and hypothalamus to stop the secretion of 
FSH and LH. The resulting negative feedback leads to deterioration of 
corpus luteum, which further decreases the amount of estrogen and 
progesterone [5].
The contraceptive pills work on the same hormonal axis mentioned 
above. These drugs modulate the normal condition of this hormonal 
regulation, which delays the follicle development in females. There are 
different categories of hormonal contraceptives and different mode of 
administration. Although, this study is focused only on COC pills and 
progesterone-only pills.
CATEGORY OF HORMONAL CONTRACEPTIVES PILLS
Previously, administration of COCs used to deliver a dose of high 
EE or mestranol along with progestin, resulting in increased risk of 
cardiovascular disease. However, the therapeutic combinations of COC 
have substantially changed over the past few decades (Fig. 3). Current 
COCs contain a low dose of EE or estradiol (E2) combined with new 
progestins, and many alternatives or nonoral routes of administration 
have been evolved. Besides, progestin-only contraceptive pills are a 
contraceptive method that may be the better option for women with 
several routes of administration are available these days [6].
ORAL ROUTE OF ADMINISTRATION
OCs can be categorized into two main categories:
• COC pills and
• Progestin-only pills (POPs).
COCS PILLS
Synthetic estrogen (with high dose) and androgenic progestin like 
norethisterone acetate or norethindrone had been marketed as the first 
COC. The present COCs deliver low doses of EE every day. E2 valerate 
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and dienogest have been newly approved in Europe and the USA as 
quadriphase OC. Another monophasic COC that combines E2 with 
nomegestrol acetate, a progesterone-derived progestin, is now being 
marketed in several countries in Europe [7-9].
Estrogen in COC
The dose of estrogen has been decreased by drug companies to reduce 
the risk of cardiovascular disorders. The estrogen component, EE or 
17α estradiol is used in COCs available these days (Table 1). Over the 
years, the dose of EE has reduced from 50 to 30-35 mg and gradually 
to 20-15 mg. Pills are now segregated into higher and lower than 
30 mg dose of EE. This reduction has been made feasible due to the 
accessibility of new classes of progestin. In the 1970s, the concept 
arose to use the natural 17β estradiol in COCs, although no satisfactory 
formulations were available for years. In few cases, the pills containing 
17β-E2 were contraceptive, but females showed low tolerance 
experiencing excessive bleedings. There are two combinations have 
been commercialized containing estradiol (E2). Selective estrogen 
receptor modulators are under development, which has estrogenic 
activity on bone and endometrium but antiestrogenic activity on the 
breast, e.g., estetrol [3].
Progestins in COC
In the different combined pills available nowadays, the progestin 
component in the pill inhibits LH peak, decreases ovarian sensitivity 
to FSH, and therefore, decreases estradiol production. The estrogenic 
component regulates endometrium proliferation and compensates 
estrogenic deficiency induced by the antigonadotropic effect of 
the progestin. Progestins are classically characterized according to 
their structural origins. They bind to progesterone receptors, but 
progestins may also bind to other steroid receptors such as androgen, 
glucocorticoid, and mineralocorticoid receptors. Most of the progestins 
contained in COCs were initially derived from testosterone and are 
called 19-nortestosterone derivatives. Norethisterone is an estrone, 
and norethisterone acetate and norethynodrel are gonanes. Few pills 
containing first-generation progestins are still available. Their side 
effects such as acne, oily skin, and decreased high-density lipoprotein, 
mainly due to their androgenic properties, are the primary cause for 
their progressive withdrawal. Over the years, progestins with less 
androgenic effects have been developed (Table 2). Levonorgestrel 
(LNG) and norgestrel are second-generation progestins. Third-
generation progestin includes desogestrel (DSG), with its active 
metabolite 3-keto-DSG (also named etonogestrel), norgestimate (and 
its active 17-deacetylated metabolite, norelgestromin [NGMN]), and 
gestodene (GSD) [3].
Different progestins used in COCs are derived from progesterone. 
Molecules such as chlormadinone acetate, cyproterone acetate (CPA), 
and medroxyprogesterone acetate are called pregnane derivatives, as 
they are derived from 17-OH progesterone [10]. Some newer progestins 
have been available more recently in OCs such as drospirenone (DRSP). 
This progestin possesses antimineralocorticoid and weak androgen 
proprieties. Dienogest is a hybrid progestin, derived from the estrane 
group but does not exert the androgenic effects of the testosterone 
derivatives. A Cochrane review evaluated the effectiveness and side 
effects of different progestogens [11]. In this comparative study, 
13,923 participants were included in a total of 30 trials enabling 
16 comparisons. The conclusion of this Cochrane Review mentions 
that women using COCs containing second-generation progestogens 
may be less likely to discontinue than those using COCs containing 
first-generation progestogens. Based on one small double-blind trial, 
third-generation progestogens may be preferable to second-generation 
preparations concerning bleeding patterns, but further evidence is 
needed [3].
Millions of women have used estrogen and progestins as effective 
COCs. OCs modify surrogate markers such as lipoproteins, insulin 
response to glucose, and coagulation factors that have been associated 
with cardiovascular and venous risk. EE exerts a stronger effect that 
natural estradiol (E2) on hepatic metabolism. New progestins with high 
specificity have been designed to avoid interaction with other receptors 
and prevent androgenic, estrogenic, or glucocorticoid-related side 
effects. The risks and benefits of new progestins used in contraception 
depend on their molecular structure, the type and dose of associated 
estrogen, and the delivery route [3].
Progestin-only contraceptive pills (POPs)
POPs delivers a very low concentration of progestin every day 
(norethindrone, LNG, or DSG). While the developments of OCs pills are 
based on progestin-only components, recently POPs are less widely 
used than COC as a result of their negative uterine tolerance [12]. 
Though, POPs may be an attractive contraceptive choice for women 
with contraindications to COCs (Table 3).
ALTERNATIVE (NONORAL) MODE OF ADMINISTRATION
These types of contraceptives provide steady supplies of hormones. 
They can be delivered in a combination of estrogen and progestin or 
progestin only.
Combined contraceptives
There are two types of other (non-oral) mode of administration 
available: Patch and vaginal ring. The patch (transdermal) consists of 
EE along with NGMN and the vaginal ring consists of EE along with 
etonogestrel.
Progestin-only contraceptive
Currently, there are three major routes of nonoral administration of 
contraceptives which are frequently used in the USA and Europe [3].
Many synthetic hormonal contraceptives are available with different 
brand names, but these all contain synthetic estrogen and progesterone 
and having severe side effects. The details of few synthetic contraceptive 
drugs are mentioned in Table 4.
ADVERSE EFFECT OF SYNTHETIC CONTRACEPTIVE PILLS
It has been reported that OC pills may cause many side effects in a long 
run, and authors have discussed a few of those side effects in this article.
Table 1: Two type of combinations of estradiol [3]
Active ingredients Classification of components
Quadriphasic COC-E2 
valerate+dienogest
E2 valerate-synthetic estrogen, 




COC: Combined oral contraceptive











COCs: Combined oral contraceptives, NGM: Norgestimate, DSG: Desogestrel, 
GSD: Gestodene, LNG: Levonorgestrel
Table 3: Mode of administration of progestin [3]
Mode of administration Time duration
Injectable (intramuscular-medroxyprogesterone) 3 months
Single rod implant (LNG/etonogestrel) 3 years
Intrauterine device (low dose of LNG) 3-5 years
LNG: Levonorgestrel
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Effects on brain structure
Adult brain structure is subject to dynamic changes with age. These 
changes differentially affect brain areas, such as gray matter volumes 
in some regions, decline more strongly with age than others. An age-
related strong decline has been demonstrated in the prefrontal cortex, 
as well as the hippocampus. Recent results showed that regional gray 
matter volumes in the prefrontal cortex, as well as the cingulate anterior 
gyrus, are larger in mixed samples of androgenic and antiandrogenic 
OC users compared to nonusers [22]. These regions are already larger 
in women when compared to men. However, regional gray matter 
volumes of OC users were also greater in the cerebellum, hippocampi, 
parahippocampus, and fusiform gyri [23]. Those regions are on the 
average larger in men compared to women. Results from rodent 
hippocampi suggest that these volume increase may be attributed to an 
increase in synaptic spin density mediated by estrogen receptors [24], 
but an increase in astrocyte volume in response to estradiol has also 
been suggested [13].
Hormonal contraceptives and risk of venous thromboembolism 
(VTE)
It has been reported that VTE risk is related to COC [25]. The risk of VTE is 
higher during the 1st year of use depending on the different combinations 
of COCs. Recently, new formulations of OCs and nonoral routes of 
administration have been evaluated in the context of VTE risk [26-28]. 
Based on the epidemiological findings, the risk of VTE is higher among 
those using 30-35 mg of within different types of progestin as compared 
to COC containing LNG [28]. With the same doses of EE (30-35 mg), the 
COC-containing DRSP, EE CPA, DSG, or GSD also increased the risk of VTE 
as compared to COC-containing LNG. It has also been reported that use of 
nonoral routes of combined contraceptives, patch, or vaginal ring is also 
associated with a higher VTE risk compared with the second-generation 
pills [28]. The changes found to be more deleterious to users of this new 
progestin than among LNG users. In combination with EE, these new 
progestin appears to induce resistance to activated protein C (APC), 
which is a surrogate marker of VTE risks. The effect on APC resistance of 
Table 4: List of synthetic hormonal contraceptive pills available, their mode of action and their side effect
Name Active component Mode of action Side effects References
Estradiol 
valerate
Estradiol valerate 2 mg Estrogens diffuse into their target cells 
(i.e., cells in the female reproductive tract, 
mammary glands, hypothalamus, and 
pituitary) and bind to receptor proteins
Abnormal hair growth, 
Breast tenderness, changes 
in sex drive, cramps, 
dizziness, hair loss, headache, 
lightheadedness
[13]
Femilon DSG BP 0.15 mg 
Ethinylestradiol IP 0.02 mg
Once bound to the receptor, progestins like 
DSG will slow the frequency of GnRH from the 
hypothalamus and blunt the pre-ovulatory LH 
surge
Femilon contraceptive pill unleashes ethinyl 
estradiol and DSG into the blood stream
Vaginal infections, urinary 
tract infections, Breast pains 





CPA 2 mg ethinylestradiol 
0.035 mg
Binds to the progesterone and estrogen 
receptors slowers the release of GnRH from 
the hypothalamus and blunt the pre-ovulatory 
LH surge
blood clots cancers such as 




GSD BP 60 mcg 
ethinylestradiol 15 mcg
Estrogens increase the hepatic synthesis 
of SHBG and other serum proteins and 
suppress FSH from the anterior pituitary. The 
combination of an estrogen with a progestin 
suppresses the hypothalamic-pituitary system, 
decreasing the secretion of GnRH
Severe chest pain and cough of 






DSG 0.15 mg 
ethinylestradiol 0.03 mg
Binds the estrogen and progesterone receptor, 
inhibits ovulation
Severe allergic reactions, 
bloody diarrhea, breast lumps 
pain or discharge fainting, 
frequent or painful urination 





Levonorgestrel IP 0.15 mg 
ethinylestradiol 0.03 mg
It inhibits ovulation, prevents transport of 
sperm or eggs and thus prevents fertilization 
and alters the lining of the uterus to prevent
Ovipauz-levonorgestrel 
may cause thrombotic and 
thromboembolic disorders, 
vascular problems, hepatic 
neoplasia, carcinoma of 
breasts and reproductive 
organs, gallbladder disease, 
ocular lesions
[18]
Crisanta LS Ethinyl estradiol 0.02 mg 
DRSP 3 mg
Progestins such as DRSP diffuse freely into 
target cells in the female reproductive tract 
and bind to the progesterone receptor. And 
block the GnRh release and LH surge





Levonorgestrel IP 0.25 mg 
ethinylestradiol 0.05 mg
Levonorgestrel tricks the body processes into 
thinking that ovulation has already occurred, 
by maintaining high levels of the synthetic 
progesterone. This prevents the release of 
eggs from the ovaries
Local skin reaction, 
depression, liver impairment, 
reduce menstrual loss
[20]
Ovral G Norgestrel 0.5 mg 
ethinylestradiol 0.05 mg
The combination of an estrogen with a 
progestin suppresses the secretion of GnRH
Stomach cramping, Vomiting, 
dizziness
[21]
DRSP: Drospirenone, CPA: Cyproterone acetate, DSG: Desogestrel, GSD: Gestodene, SHBG: Sex hormone binding globulin, GnRH: Gonadotropin-releasing hormone
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the different molecules of progestin associated with the same EE dose has 
been clearly investigated. It has been found that acquired APC resistance 
(measured as the effect of APC on thrombin generation) may be related to 
the thrombotic effect of hormonal contraceptives. Sex hormone binding 
globulin (SHBG), a carrier protein synthesized by the liver, has found to be 
positively correlated with APC resistance among pill users. It is, therefore, 
another useful pharmacological marker to predict the thrombotic venous 
safety of a combined contraception indirectly. Hence, SHBG appears to be 
higher among users of DSG, DRSP, and CPA containing pills as compared 
to those using LNG pills [29-31].
CONCLUSION
Contraceptive pills mainly work by inhibiting or delaying ovulation and 
up to some extent preventing fertilization and implantation. Several 
clinical studies have shown that COCs works primarily on either 
inhibiting or delaying ovulation. Millions of women in this reproductive 
age (14-45 years) are taking these medicines to delay pregnancy. 
Many of the women have experienced side effects after taking COCs 
or POPs such as spotting, weight gain or weight loss, nausea, breast 
tenderness, severe headache, depression, darkening skin, and vaginal 
infection. There is sufficient evidence in humans that combined oral 
estrogen-progesterone contraceptives are carcinogenic in nature. This 
assumption has made by increased risk for cancer of breast, cervical, 
and liver. However, experiments in animals have provided inadequate 
evidence for the carcinogenicity of progesterone, LNG, norgestrel, or 
progestin-derived contraceptive pills. These contraceptives act as LH 
receptor (LHR) and progesterone hormone receptor (PGR) inhibitors 
and thus in long-term usage interferes with the ovulation cycle which 
results in premature ovulation or delayed ovulation. However, herbal 
compounds have been found to work as partial inhibitors of LHR and 
PGR, and at the moment, they are being removed from the system, the 
ovulation cycle is retained. Collectively, there is a need to work for herbal 
analogs of these contraceptives which can be effective as well as safe.
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